Arcellx (ACLX) | Stock Overview & Key Data
Arcellx Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $107.37 on November 11, 2024
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Arcellx ACLX | 3.51B Mid-cap | 2.89% | -0.45% | 24.18% | -7.89% | -15.48% | 5.00% | 293.22% | 290.18% |
| Vertex VRTX | 114.06B Large-cap | 3.14% | 4.53% | -1.27% | 13.16% | 14.93% | -6.00% | 56.88% | 55.98% |
| Regeneron REGN | 55.27B Large-cap | 2.40% | 5.82% | -1.63% | -25.33% | -23.41% | -51.08% | -11.43% | -16.45% |
| Blueprint Medicines BPMC | 8.29B Mid-cap | 0.05% | 0.34% | 62.08% | 41.67% | 47.25% | 9.02% | 139.78% | 65.31% |
| Roivant Sciences ROIV | 7.82B Mid-cap | -0.73% | -1.99% | 19.60% | -1.45% | -10.10% | -5.37% | 151.52% | 8.27% |
| Bio-Techne TECH | 7.92B Mid-cap | 1.15% | 5.61% | 7.93% | -29.94% | -26.30% | -33.33% | -40.13% | -26.31% |
Ownership & Short Interest
Arcellx Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Arcellx would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
-
In the last 52 weeks, Arcellx reached a high of $107.37 (on November 12, 2024) and a low of $47.86 (on May 7, 2025).
-
Curious about Arcellx's size and valuation? Its market capitalization stands at 3.51B. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is -28.28.
-
As for dividends, Arcellx isn't currently offering a significant yield, or that specific data isn't available right now.
-
When looking at Arcellx, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX114.06B Healthcare Biotechnology -6.00% 56.88% Regeneron
REGN55.27B Healthcare Biotechnology -51.08% -11.43% Blueprint Medicines
BPMC8.29B Healthcare Biotechnology 9.02% 139.78% Roivant Sciences
ROIV7.82B Healthcare Biotechnology -5.37% 151.52% Bio-Techne
TECH7.92B Healthcare Biotechnology -33.33% -40.13% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
-
To get a sense of Arcellx's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -35.56%, the Debt to Equity ratio from the most recent quarter is 12.76, and its Gross Profit Margin stands at N/A.
-
Looking at Arcellx's growth, its revenue over the trailing twelve months (TTM) was $77M. Compared to the same quarter last year (YoY), quarterly revenue grew by -79.30%, and quarterly earnings saw a YoY growth of -79.29%.
-
Wondering who owns Arcellx stock? Company insiders (like executives and directors) hold about 14.50% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 102.08%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.